Fred Dorey is a Special Counsel in the Life Sciences and Clean Technology Groups of Cooley Godward Kronish, LLP in Palo Alto, CA, where he represents biotechnology, clean energy and technology companies. His practice includes corporate formation and finance, technology licensing and strategic partnering. He also represents a number of foundations, research institutes and universities.

Prior to joining Cooley, Mr. Dorey helped organize, and was the first President of the Bay Area Bioscience Center, (now BayBio), the regional consortium of research universities, companies and local governments that promotes biotechnology in Northern California.  He also served as part-time general counsel to several early-stage biotechnology companies. Previously he was General Counsel of the subsidiary of British Petroleum that handled all of BP’s oil exploration and production in the United States, and served with the Office of International Affairs of the Department of Energy in Washington DC.

He is a director of Community Health Charities, the BayBio Institute, and serves as a member of the Beachheads program of the New Zealand government, and the Advisory Board of the Gladstone Institutes.

He received his J.D. from the University of Southern California and a B.S in Engineering from UCLA.

Twenty-five years of public accounting and private industry experience. Experience in the technology, health care, semiconductor, and biotechnology industries. Consults with management on a variety of accounting and tax services including financial statements, SEC audits, audits of VC backed start ups, implementation of accounting systems, preparation of forecasts and budgets, litigation support and business plan development. Certified Valuation Analyst.

Education

MS/Taxation - Golden Gate University
BA/Business Economics - University of California, Santa Barbara
Graduate of Leadership Mid-Peninsula

Activities

Board of Directors - Eldercare Alliance
Member - Quality Inspection Team, American Institute of Certified Public Accountants (AICPA)
Member - California Society of CPAs (CalCPA)
Member - Healthcare Financial Management Association (HFMA)

Interesting Tidbit: Traveling adventures include meeting a shark while snorkeling the Great Barrier Reef, river rafting down the “Shot Over” river in New Zealand, hiking to the top of Interlaken Mountain in Switzerland, and braving a small plane ride through a rainstorm in Costa Rica!

Susan M. Baxter has served as executive director of the California State University Program for Education and Research in Biotechnology (CSUPERB) since March 2007. Currently she serves on boards at the BIOCOM Institute, the nonprofit arm of the biotechnology industry association in southern California, California Healthcare Institute and Histogen, private early stage regenerative medicine company. Before joining CSUPERB, Baxter served as chief operating officer at the National Center for Genome Resources, where she managed a portfolio of state- and federally-funded projects providing software for collaborative genome and population genetics research teams. Previously Baxter was vice president of research and genome analysis at GeneFormatics, later Cengent, and a tenured researcher at the New York State Department of Health’s Wadsworth Center. Baxter began her career at Monsanto Agricultural Company where she received a Monsanto Company Achievement Award for product development. Baxter received her Ph.D. degree in chemistry from Northwestern University and a bachelor’s degree in chemistry from the University of Virginia.

Throughout a distinguished career, Dr. Lacey has focused on the use of science and technology to help create new medicines that make a difference in the lives of patients. Dr. Lacey received both his BA (1976) and MD (1983) from the University of Colorado and his accomplishments were recognized through his nomination to Phi Beta Kappa and Alpha Omega Alpha, respectively.

To pursue his research interest in bone biology in conjunction with completing his post graduate medical education, he relocated to Washington University, St. Louis, Missouri. Recognized as a leader, he served as Chief Resident of Anatomic Pathology his final year of training. He remained at Washington University where he taught pathology residents and medical students, performed professional medical service in anatomic pathology, and pursued NIH-funded research in bone cell biology.

In 1994, he switched from an academic career to one in industry when he moved to California and joined Amgen. Initially starting as an associate medical director in a research-oriented pathology group he quickly assumed the leadership position and thus began a continuous string of appointments of increasing scope and complexity within the company so that by 2000 he was Vice-President of Pharmacology/Pathology in Preclinical Development leading a group of ~ 145 FTE. In mid-2006, he assumed the head of Discovery Research (> 1200 FTEs) for Amgen as an interim appointment which was made permanent with his promotion to Senior Vice-President in May of 2007. In this capacity, he charted the course and motivated a diverse senior team of scientific leaders from different disciplines as well as engaging and managing a diverse stakeholder network. From his vantage point he also participated as a member of strategic committees charged with over site of Amgen’s R & D portfolio. In this capacity, he advised on project decisions including advance, maintain, or terminate. At any given time there were over 100 actively managed preclinical projects across four therapeutic areas: hematology/oncology, inflammation, metabolic disorders, and neuroscience. One unique aspect of this experience was that both small and large molecule projects were adjudicated together within a single portfolio, in the same meetings, and at the same time. Amgen’s pipeline excellence has been recognized externally by Scrip (November 2009) and R&D Directions (January 2011).

Scientifically, he played a fundamental role in the discovery of the OPG/RANKL/RANK pathway at Amgen which led to the development of the anti-RANKL human mAb denosumab, an emerging dual blockbuster for both osteoporosis and cancer-related bone diseases. Denosumab has received a number of awards including the US 2011 Prix Galien award for best new biotechnology product and the 2010 Scrip award for best new drug. Additionally, the early work in this area was pivotal in garnering the research collaboration with UCB Celltech on sclerostin, perhaps leading to the next “DMAB” for bone disorders.

As a seasoned, experienced biopharmaceutical executive he views the challenges of discovery research in the current post-genome era as highly competitive, facing increasing regulatory complexity, but opportunity rich requiring the coordination and understanding of diverse scientific specialties and newly evolving, disruptive technologies including for instance next gen sequencing. In his opinion, to be a successful leader in industry, the most important skills to possess in addition to the requisite technical ones are the ability to listen and discern, lead effectively by example, motivate, and make decisions in the absence of “perfect” data.

Dr. Lacey recently retired (July 2011) from Amgen and is providing consulting/advising services to the established and start-up biotechnology community including those arising within academic institutions. Tapping into his experience could be useful in the areas of project and portfolio decisions, organizational design and process, and leadership.

Gail Maderis is President and CEO of BayBio, the industry organization representing and supporting Northern California’s life science community. As a former biotech CEO, Ms. Maderis brings deep experience and commitment to supporting the industry through enterprise development, peer-to-peer experience sharing, advocacy and support of education and workforce development. From 2003 to 2009, Ms. Maderis served as President and CEO of Five Prime Therapeutics, Inc., a privately held protein discovery and development company. At FivePrime, she successfully funded the company’s rapid growth through substantial private equity financings and corporate partnerships and took the company’s first novel cancer therapeutic from discovery into clinical trials. Prior to FivePrime, Ms. Maderis held senior executive positions at Genzyme Corporation, including founder and president of Genzyme Molecular Oncology (GZMO). Ms. Maderis practiced management and strategy consulting with Bain & Co. She serves on the boards of BayBio, the Mayor’s Biotech Advisory Council of San Francisco and the HBS Healthcare Initiative. She received a BS in business from the UC Berkeley and an MBA from Harvard Business School.

Sandra Young is responsible for site communications and philanthropy at Amgen’s research sites in South San Francisco, California, and Cambridge, Massachusetts. This includes internal and external communications, media and community relations, philanthropic efforts and civic relationships. She joined Amgen in 2006.

Additionally, Sandra currently serves as a Captain in the United States Navy Reserve. Sandra graduated from the United States Naval Academy in the first class that admitted women. She has served both on active duty and in the reserves. Sandra was mobilized back to active duty for about 2 years following the 9/11 attacks.

Sandra and her husband live in Cambridge, MA.

Michael A. Alvarez is the founder and serves as Director of the Stanford University School of Medicine Career Center, established in 2004. Since its inception, he has successfully built relationships with external organizations across a wide spectrum, including early stage biotechnology, big pharma, medical device, legal, and the banking and finance sectors, to facilitate commercialization and new venture formation, and to support the professional development of clinicians and researchers. His professional experience of more than 17 years spans both business and academic settings, including coaching NCAA Division I wrestling and teaching at Boston College, management consulting as part of Accenture's NYC practice, founding and directing the UCSF Career Center – introducing innovative entrepreneurship and business curricula - and providing independent consultation to life science companies in the areas of organizational design and business strategy. He is widely sought for input and expert opinion on labor market trends, technology commercialization, and medical science training, and has written, reviewed, and published many articles on these topics in Nature and other major media venues. Michael holds bachelor’s and master's degrees from Boston College, a certificate in Intellectual Property Management from the University of Washington, and studied business at IESE in Barcelona, Spain. He is a member and vice chairman of the board for Bay Bio and the Bay Bio Institute respectively.

Douglas Crawford, Ph.D., is the Associate Director of QB3 (the California Institute for Quantitative Biomedical Research): a research institute that brings together more than 200 faculty on the UCSF, UC Berkeley, and UC Santa Cruz campuses. His goal is to help stimulate economic growth in the State of California by promoting cross-discipline academic research and then accelerating the transfer of the resulting innovations to the market. For instance, he created and manages the first incubator within the University of California, the QB3 Garage@UCSF, QB3 Mission Bay Incubator Network, and QB3 Garage@Berkeley. Together these incubators have helped launch 29 companies. Crawford is also a founder and Managing Director of Mission Bay Capital, an $8.5 M seed-stage venture fund seeks to make pivotal early-stage investments in bioscience companies emerging from the UC. He is a board member of the BayBio Institute and BioE2E; and a board observer for Redwood Biosciences. Crawford received his Ph.D. in Biochemistry at UCSF.

Dr. Moira Gunn is best known as the host of Tech Nation, which airs nationally on the National Public Radio channels on Sirius-XM and each weekend on NPR’s 24-hour program stream (Click “Listen” at npr.org). The program is also carried on public radio stations nationwide, to 177 countries via American Forces Radio International, and through popular podcasts on the Internet. In 2004, Tech Nation added the regular segment BioTech Nation to address the expanding field of biotechnology. To date, Tech Nation has carried over 3,000 interviews on tech, biotech and science and aired over 500 commentaries on its impact on society.

Gunn holds a Ph.D. in Mechanical Engineering from Purdue University along with a Masters in Computer Science. A former NASA engineer and scientist, she holds a software patent in nutrition research, has been named a Science Journalism Laureate, and has received an honorary doctorate of science from Purdue University for her contributions in science communications. Her book “Welcome to BioTech Nation … My Unexpected Odyssey into the Land of Small Molecules, Lean Genes, and Big Ideas” was cited by the Library Journal to their Best Science Books list.

A professor in the School of Business and Professional Studies at the University of San Francisco, Gunn founded the MBA Biotechnology sequence, which focuses on the business of biotech – locally, nationally and globally.

Mr. Iwata has over 18 years experience in structuring and underwriting debt financing to private and public companies.   While at Comerica, he has been involved in financing as little as $250,000 to a Series A pre-revenue company, and up to $100 million in a bank debt syndication to a public company to fund acquisitions.  He joined Comerica Bank in 2001 through Comerica’s acquisition of Imperial Bank.  Mr. Iwata had been part of Imperial Bank’s emerging growth division which was focused primarily on debt financing to venture backed companies.  He currently heads the bank’s life science practice in Northern California responsible for lending to venture and public life science companies as well as managing the relationship with life science venture firms in Northern California.  Prior to joining Comerica Bank, he spent 10 years at Union Bank where he was a Vice President and Relationship Manager.  While at Union Bank, Mr. Iwata was involved in providing growth financing to local and foreign owned companies in various industries.    

He holds a B.A in Economics from San Francisco State and M.B.A from San Diego State University.

Dr. Elaine Johnson is the Executive Director of Bio-Link, a National Science Foundation Advanced Technological Education National Center for Biotechnology and Related Life Sciences based City College of San Francisco.  Elaine is a leading advocate for educating biotechnology technicians using the resources of community and technical colleges.  She serves on local, regional, and national educational, governmental and industry advisory panels and boards.   She holds degrees in chemistry & physics, microbiology, nutrition, and educational administration.  She has been a Faculty Fellow at Lawrence Berkeley National Laboratory and has participated in the development of the National Skill Standards for Bioscience and their integration with the Agricultural Biotechnology Standards.  Elaine specializes in creating partnerships between educational institutions and industry.  She promotes articulation between educational institutions in the effort to create career pathways.  She is an active member of the UCSF Community Advisory Group (CAG) and Public Science Project.  She serves on the Board for the BayBio Institute and Bay Area Biotechnology Education Consortium (BABEC) as well as being a member of the Minnesota Biosciences Education-Industry Partnership Council.  Elaine co-chaired the Outreach and Education Committee for BIO 2004 and helped organize and present at the Community College Workforce Day for BIO 2004, 2005, 2006, 2007, 2008, 2009 and 2010.  She has been by invited by the American Association for the Advancement of Science (AAAS) to a working conference on Transforming Undergraduate Education in Biology: Mobilizing the Community for Change.  Elaine is nationally recognized as an innovator and leader in providing education for careers in biotechnology and related life sciences.

Nola Masterson is Managing Director of Science Futures LLC.  Science Futures is a 26 year old investment and advisory firm.  Ms. Masterson is a biotechnology industry leader and forward thinker with more than 32 years of business experience in the life sciences industry and in venture capital investment.  From 2000 to 2005, she was a Venture Partner with TVM Capital GmbH, one of the first and largest venture capital firms in Germany.  She was a co-founder and President of Sequenom, Inc., a DNA sequencing company which went public on Nasdaq in 2000, and wrote the first business plans for IDEC and Insight Vision, as a consultant to Kleiner Perkins Caufield & Byers, and for ReSound, with Dr. Rodney Perkins, the founder of ReSound.  She was the first biotech analyst on Wall Street for Drexel Burnham and Merrill Lynch.  

Ms. Masterson is a member of the Board of Directors of Repros Therapeutics Inc. (RPRX) and Generex Biotechnology Corporation (GNBT), both Nasdaq-traded companies, and serves on the Audit Committee and Compensation Committee of both companies.  She also is on the Board of Directors of Omicia, Inc., an early-stage pharmaco-genomics company.  She is Chairwoman of the BayBio Institute, a non-profit organization serving the Northern California life sciences industry by focusing on best practices, entrepreneurship, workforce development and science education, and also serves on the Board of Advisors to Astia, a non-profit organization dedicated to advancing women entrepreneurs.  She also is on the Board of Advisors of the Professional Women’s Healthcare Alliance and of BioAgenda.  She is a graduate of the Stanford Law School Board of Directors College course.

In 2003, she was included in Irish America magazine’s annual “Business 100” and received the Alumni Achievement Award from Marymount College at Fordham University in 2004.

Mr. Peterson brings broad executive general management, multi-functional, multi-business and international experience to Target Discovery, Inc., which he co-founded and has led as CEO since 1999. TDI is developing the next generation of clinical diagnostics, offering higher value molecular insights for the diagnosis and personally optimized management of disease (“personalized medicine”). The company’s initial commercial focus is on the new class of protein isoform biomarker diagnostics (Isonostics™) that better guide therapeutic choices for cancer and lower the overall costs of cancer treatment. The company engages in funded collaborations with partners, for application of its unique isoform-level technologies in other disease areas and in theranostic applications (diagnostic testing to select or disqualify patients for a specific drug therapy).

Steve has been active in partnering with technology and life sciences clients for more than 25 years. Having launched Woodruff-Sawyer's Life Sciences Practice, he has been instrumental in taking it to its current position as one of the country's largest over the last 20 years.  Under Steve’s leadership, Woodruff-Sawyer was selected by the Biotechnology Industry Organization (BIO) as its West Coast risk management partner.  This was a direct result of the company’s long history servicing life sciences companies and its ability to customize policies to meet the industry's unique needs.  Steve has worked with companies from new venture formations through IPO and all stages of commercial development on strategic issues involving risk management and insurance program design. 

Steve regularly speaks on risk management and securities litigation exposures relating to emerging and public companies. He has served as a panelist for the Biotechnology Industry Organization, the Association of Bioscience Financial Officers, BayBio, Mealey's and the Chartered Property and Casualty Underwriters (CPCU) Society, as well as continuing education for CPAs and attorneys.

Steve is a member of the Board of Directors of Woodruff-Sawyer & Co.   He earned his bachelor's degree from Stanford University and his MBA from Northwestern University.    He is currently on the Board of the BayBio Institute, and serves on boards and as a volunteer for various non-profit foundations and organizations.